Compared to Dupilumab Upadacitinib rapidly improves itching and clears skin in atopic dermatitis: JAMA
Upadacitinib vs Dupilumab in adult atopic dermatitis (AD) : JAMA study
Atopic dermatitis is a severely pruritic relapsing disorder with multiple cytokines like interleukins (IL) like IL- 4, 13, 22,-31, interferon gamma (IFN-γ) and thymic stromal lymphopoietin (TSLP) involved in its pathogenesis. Dupilumab, a monoclonal antibody against α-subunit of IL-4 and IL-13 receptors is approved for the treatment of moderate-to-severe AD. Upadacitinib is an oral, reversible, selective JAK1 inhibitor recently showing evidence of efficacy in AD.2
The present study was a head-to-head, multicenter, randomized, double-blinded, double dummy, active-controlled 24-week clinical trial conducted from February 21, 2019, to December 9, 2020 comparing the safety and efficacy of upadacitinib vs dupilumab in adults with moderate-to-severe AD. Eligible patients diagnosed with moderate to severe AD requiring systemic therapy were recruited.
Criteria for moderate to severe disease was defined as either one or all of the following-≥
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.